StoryFunding
Isomorphic Labs raises $600M in its first external round, led by Thrive Capital
Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and existing backer Alphabet. Funds support development of its next-generation AI drug design engine and clinical advancement of its own therapeutic programs.
- Lead investor: Thrive Capital; participants: GV, Alphabet.
- First external round for the DeepMind subsidiary focused on AI-driven drug discovery.
- Funds: AI drug design engine development and therapeutic program advancement to clinic.
- Isomorphic Labs applies AlphaFold and related AI to discover novel protein-based medicines.